PDX models are becoming more widely recognized as an effective tool for identifying cancer characteristics, developing novel treatments, and forecasting therapeutic success. In recent years, attempts to develop PDX models of ovarian tumors to understand carcinogenesis have increased. The rate of engraftment varies according to the type of malignancy and tumor. Engraftment success rates for cervical cancer PDX models ranged from 66.7% to 71.4%, while engraftment success rates for endometrial cancer PDX models ranged from 60% to 86%. The success rate of ovarian cancer engraftment in PDX models ranged from 45.5% to 100%.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/global-pdx-models-market
Global Patient Derived Xenograft (PDX) Models Market was valued at USD 142,396.93 million in 2021 and is expected to reach USD 500,362.17 million by 2029, registering a CAGR of 17.01% during the forecast period of 2022-2029. One of the major factors driving the growth of the patient derived xenograft (PDX) models market is the rise in demand for personalized medicine around the world. The ongoing public and private sector support for cancer research in the form of funds and investments accelerates market growth. The ongoing public and private sector support for cancer research in the form of funds and investments accelerates market growth.
Growing demand for personalized medicine across the globe is expected to drive the market's growth rate
Personalized medicine is the tailored treatment to the individual distinctive of each patient. Personalized medicine has the prospective to alter the way we think about identification and management of existing and upcoming health problems. Due to the similarities between actual world patients and PDX models, these models are often used in translation fidelity in the progress of personalized medicine. These models have unique characteristics due to which they are in demand to sustain a close fidelity to the parental tumor tissue.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Mice Models, Rat Models), Tumor Type (Respiratory Tumor Models, Urological Tumor Models, Gastrointestinal Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Others), Application (Preclinical Drug Development and Oncology Research, Biomarker Analysis), End User (Contract Research Organization, Academic and Research Institutions, Pharmaceutical and Biotechnology Companies)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Crown Bioscience Inc. (U.S.), THE JACKSON LABORATORY (U.S.), Champions Oncology, Inc. (U.S.), Charles River Laboratories (U.S.), Wuxi AppTec (China), Oncodesign (Canada), Aragen Bioscience (India), Biocytogen (U.S.), Bioduro (U.S.), Creative Animodel (U.S.), Covance Inc. (U.S.), EPO Berlin-Buch GmbH (Germany), EUROPDX. (Belgium), Explora BioLabs (U.S.), Hera BioLabs (U.S.), Horizon Discovery Ltd. (U.K.), Pharmatest Services (Finland), Urospehere SAS (Cyprus), Xentech (France), Xenopat (France) among others
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
Global patient derived xenograft (PDX) models market is segmented into four six segments on the basis of type, tumor type, application, technique, end user and distribution channel.
- On the basis of type, the global patient derived xenograft (PDX) models market is classified into mice models and rat models. In 2021, mice models dominated the market and is expected to reach USD 382,252.33 thousands by 2029 along with the highest CAGR of 17.3% in the forecast period of 2022 to 2029. This is because of the growing number of research and development proficiencies involving the use of mice models.
- On the basis of tumor type, the global patient derived xenograft (PDX) models market is classified into gastrointestinal tumor models, lung tumor models, hematological tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, and others. In 2021, gastrointestinal tumor models segment dominated the market and is expected to reach USD 246,623.76 thousands by 2029 along with the highest CAGR of 17.0% in the forecast period of 2022 to 2029. Rising number of gastrointestinal tumours at global level is bolstering the growth of this segment.
- On the basis of application, the global patient derived xenograft (PDX) models market is classified into basic cancer research, preclinical drug development, biomarker analysis, co-clinical trials and precision medicine. In 2021, basic cancer research segment dominated the market and is expected to reach the USD 229,658.10 thousands by 2029 along with the highest CAGR of 16.3% in the forecast period of 2022 to 2029. Growing expenditure for research and development activities driven towards cancer research is bolstering the growth of the segment.
- On the basis of technique, the global patient derived xenograft (PDX) models market is classified into heterotopic implantation and orthotropic implantation. In 2021, heterotopic implantation segment dominated the market and is expected to reach the USD 423,459.22 thousands by 2029 along with the highest CAGR of 16.8% of in the forecast period of 2022 to 2029.
The heterotopic implantation segment dominates the wound type segment of the patient derived xenograft (PDX) models market
- In 2021, heterotopic implantation segment emerged as the dominating segment. This is because of the growing awareness about the benefits of heterotopic implantation will further bolster the growth of the market. Also, growth and expansion of the healthcare industry and increasing personal disposable income will yet again bolster the growth and dominance of this segment.
- On the basis of end user, the global patient derived xenograft (PDX) models market is classified into academic & research organizations, contract research organizations & pharmaceutical and biotechnology companies. In 2021, academic & research institutions segment dominated the market and is expected to reach USD 351,297.33 thousands by 2029 along with the CAGR of 16.5% in the forecast period of 2022 to 2029.
The academic & research institutions dominates the end user segment of the patient derived xenograft (PDX) models market
- In 2021, academic & research institutions segment emerged as the dominating segment. This is because of the growing number of infrastructural facilities in the developing economies such as India and China. Also, growing number of medical professionals further bolstered the growth of the market.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players: Crown Bioscience Inc. (U.S.), THE JACKSON LABORATORY (U.S.), Champions Oncology, Inc. (U.S.), Charles River Laboratories (U.S.), Wuxi AppTec (China), Oncodesign (Canada), Aragen Bioscience (India), Biocytogen (U.S.), Bioduro (U.S.), Creative Animodel (U.S.), Covance Inc. (U.S.), EPO Berlin-Buch GmbH (Germany), EUROPDX. (Belgium), Explora BioLabs (U.S.), Hera BioLabs (U.S.), Horizon Discovery Ltd. (U.K.), Pharmatest Services (Finland), Urospehere SAS (Cyprus), Xentech (France), Xenopat (France).
Market Development
- GemPharmatech (GemPharmatech Co., Ltd.) announced in July 2022 that it has signed a strategic licence agreement with Charles River Laboratories, Inc. for the exclusive distribution of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. Beginning in 2023, Charles River will establish foundation colonies with commercially available models.
- Professor Kamimura's research group at Niigata University established a novel pancreatic carcinogenesis model in wild-type rats in April 2022, using the pancreas-targeted selective hydrodynamic gene delivery method.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada and Mexico in U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in patient derived xenograft (PDX) models market during the forecast period 2022 to 2029
North America had the greatest share. An increase in cancer cases, rising governmental and private sector investments, and the presence of key players in the field are all major factors. The breast cancer research project chosen for funding will improve the care of Canadian women with breast cancer by focusing on improvements in screening, detection, precision oncology, and patient-reported outcomes.
Asia-Pacific is estimated to be the fastest-growing region in patient derived xenograft (PDX) models market the forecast period 2022 to 2029
As a result of China's high research spending and well-developed CRO sector, Japan's expansion in biomedical and medical research, India's rising pharmaceutical R&D spending, and Singapore's expanding translational and biomedical research, Asia-Pacific is expected to be the fastest-growing region over the forecast period.
COVID-19 Impact Analysis
Given the decline in productivity in life science organizations during the pandemic, COVID-19 had a negative impact on the patient derived xenograft (PDX) models market. Reduced pharma R&D deals in therapeutic areas, disruption of clinical trials, and country-specific lockdowns all had an impact on the market. Oncology, ID/anti-infectives, cardiovascular disease, and respiratory disease were the most affected trials. The market will re-grow as the impact of COVID-19 is expected to fade in the post-pandemic scenario.
For more detailed information about the patient derived xenograft (PDX) models market report, click here – https://www.databridgemarketresearch.com/jp/reports/global-pdx-models-market
